ANALYSTS
HAD expected a blistering earnings season for European banks, which
reported their second-quarter results in late July and early August. And
painfully hot it was, with profits melting away as lenders made
provisions for future loan losses. On August 3rd HSBC, Europe’s largest
bank by assets, said that its post-tax profits had fallen by 88% on the
year, to $617m. Loss-making lenders included Deutsche Bank in Germany,
Santander in Spain and Société Générale in France.
Much
like Wall Street titans, albeit on a smaller scale, European lenders
with investment-banking arms saw losses tempered by a boost in trading
revenue. As the coronavirus spread and markets turned volatile,
investors rushed to reposition their portfolios. Many governments and
companies took advantage of central-bank support and ultra-low interest
rates to issue debt, allowing banks to pocket fat fees. BNP Paribas,
France’s largest bank, saw trading revenue jump by 154%.
Such
frenetic activity seems unsustainable. Indeed, says Stuart Graham of
Autonomous, a research firm, debt issuance appears to have slowed in
July. So the fate of banks will primarily be decided by the extent to
which they are prepared for loan losses. Lenders on either side of the
Atlantic have taken different approaches to the matter, with European
banks booking smaller provisions, as a share of total loans. American
banks have generally been more cautious in the past, only for European
rivals to play catch-up (see chart). So who is right this time?
There
is reason to think America’s banks may suffer more. Unemployment there
has surged; Coface, a credit insurer, expects bankruptcies over the next
year or so to rise by more than in Europe. A larger portion of American
bank lending, including consumer and high-yield credit, is riskier and
unsecured. European banks prefer to lend against collateral, for example
through mortgages. That implies fewer and slower defaults, as well as
higher recovery rates, when the cycle turns.
But
the economic outlook is not the full explanation. America’s accounting
rules require its lenders to make provisions against losses they expect
on all loans over their lifetime. European rivals are required to
account for lifetime losses only on loans that are closest to default
(for performing assets they need to care only about the next 12 months).
That makes them mechanically more myopic. In March the European Central
Bank (ECB) encouraged more optimism by telling them to “avoid
excessively pro-cyclical assumptions” when making provisions—in other
words, to ensure that lending does not seize up in bad times.
Cultural
differences compound prudential ones. American businesses, fans of
transparency, ted to shoulder more pain upfront. European ones prefer
to wait and see. Disclosure is not helped by the fact that fewer banks
are listed. Only half of the 84 euro-zone lenders deemed “significant”
by the ECB are publicly traded, says Nicolas Véron of Bruegel, a
think-tank. By contrast, all America’s big banks are listed.
European
banks’ smaller provisions could also be an admission of weakness. Most
entered the crisis with a pre-existing condition: low profitability.
Patrick Hunt of Oliver Wyman, a consultancy, says their return on
tangible equity averaged 6% at the start of the year, half that of their
American peers. That has left them with wafer-thin cushions with which
to absorb provisions before they eat into core capital. The vast
uncertainty about the economy translates into equally uncertain
projections for defaults—and may have given banks the leeway to book
provisions they can bear.
Investors are
not fooled. European banks’ share prices have still fallen by as much
as those in America, if not more. They have not been helped by the fact
that the ECB, in an effort to preserve capital, has forbidden banks to
distribute cash to shareholders until at least the end of the year. (In
America regulators have banned share buybacks, but only capped
dividends.) Investors usually covet European bank shares for their
stable dividends, which they then funnel into high-growth technology or
pharmaceutical stocks. The ban, says Ronit Ghose of Citigroup, a bank,
is “another nail in the coffin”.
The Economist
© The Economist
Key
Hover over the blue highlighted
text to view the acronym meaning
Hover
over these icons for more information
Comments:
No Comments for this Article